The present disclosure relates generally to formulations, compositions or foodstuff additives for use in modulating a glycemic response for treating or preventing diabetes or obesity and processes and method of its manufacture. Described is a formulation, a composition or a foodstuff for modulating a glycemic response manufactured from at least one phenylpropanoid encapsulated in a first cyclodextrin; and a second cyclodextrin. Preferably, the at least one phenylpropanoid is quercetin, phlorizin, myricetin, dihydromyricetin or any combination thereof, the first cyclodextrin is gamma cyclodextrin, and the second cyclodextrin is alpha cyclodextrin.

The present disclosure relates generally to formulations, compositions or foodstuff additives for use in modulating a glycemic response for treating or preventing diabetes or obesity and processes and method of its manufacture. Described is a formulation, a composition or a foodstuff for modulating a glycemic response manufactured from at least one phenylpropanoid encapsulated in a first cyclodextrin; and a second cyclodextrin. Preferably, the at least one phenylpropanoid is quercetin, phlorizin, myricetin, dihydromyricetin or any combination thereof, the first cyclodextrin is gamma cyclodextrin, and the second cyclodextrin is alpha cyclodextrin.

The disclosure relates to methods for treating or preventing an Insomnia Disorder by administering to a human in need thereof a compound of formula (I), or a compound of formula (IA), (IB), or (IC), or a solvate thereof, in a daily dose of from about 0.5 mg to about 6.0 mg. In certain embodiments, such compounds effectively treat or prevent an Insomnia Disorder in the animal, while producing reduced side effects compared to previously available compounds. ##STR00001##

The disclosure relates to methods for treating or preventing an Insomnia Disorder by administering to a human in need thereof a compound of formula (I), or a compound of formula (IA), (IB), or (IC), or a solvate thereof, in a daily dose of from about 0.5 mg to about 6.0 mg. In certain embodiments, such compounds effectively treat or prevent an Insomnia Disorder in the animal, while producing reduced side effects compared to previously available compounds. ##STR00001##

The invention discloses taste masking formulations for bitter natural compounds, selected from the extracts, fraction and pure phytochemicals produced in combination with a synthetic polymer or a natural polymer. The invention also relates to the novel process of producing the taste masking formulations. The invention also relates to taste masking formulations of Bacopa extracts with no bitter taste or negligible bitter taste in combination with synthetic polymers such as Eudragit or natural polymers such as Shellac.

The invention discloses taste masking formulations for bitter natural compounds, selected from the extracts, fraction and pure phytochemicals produced in combination with a synthetic polymer or a natural polymer. The invention also relates to the novel process of producing the taste masking formulations. The invention also relates to taste masking formulations of Bacopa extracts with no bitter taste or negligible bitter taste in combination with synthetic polymers such as Eudragit or natural polymers such as Shellac.

The invention discloses taste masking formulations for bitter natural compounds, selected from the extracts, fraction and pure phytochemicals produced in combination with a synthetic polymer or a natural polymer. The invention also relates to the novel process of producing the taste masking formulations. The invention also relates to taste masking formulations of Bacopa extracts with no bitter taste or negligible bitter taste in combination with synthetic polymers such as Eudragit or natural polymers such as Shellac.

A composition for use in vascular relaxation, wherein the composition includes at least one polyunsaturated fatty acid component and at least one anthocyanin component. The polyunsaturated fatty acid component is an ethyl ester of the omega-3 fatty acids eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), or an amino acid salt of EPA or DHA. The anthocyanin component is cyanidin-3-galactoside, or delphinidin-3-arabinoside. Further, the omega-3 fatty acid salt has an organic counter ion which is lysine, arginine, ornithine and mixtures of the same. The composition further includes cyanidin-3-galactoside. The composition further includes fruits extracts or cereals extracts. A method for treating a disease with the composition.

A composition for use in vascular relaxation, wherein the composition includes at least one polyunsaturated fatty acid component and at least one anthocyanin component. The polyunsaturated fatty acid component is an ethyl ester of the omega-3 fatty acids eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), or an amino acid salt of EPA or DHA. The anthocyanin component is cyanidin-3-galactoside, or delphinidin-3-arabinoside. Further, the omega-3 fatty acid salt has an organic counter ion which is lysine, arginine, ornithine and mixtures of the same. The composition further includes cyanidin-3-galactoside. The composition further includes fruits extracts or cereals extracts. A method for treating a disease with the composition.

This invention relates to compounds of Formula (I):

##STR00001##

and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein A, L.sup.2, R.sup.1, R.sup.2, R.sup.3, R.sup.4, and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts, and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.